Drug Approval | May 26, 2022
Eugia Pharma receives USFDA approval for Pemetrexed
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Subscribe To Our Newsletter & Stay Updated
